| Literature DB >> 27727166 |
Chiung-Yao Huang1, Che-Wei Chang2, Yen-Ju Tseng3, Jessica Lee4, Ping-Jyun Sung5,6, Jui-Hsin Su7,8, Tsong-Long Hwang9,10,11, Chang-Feng Dai12, Hui-Chun Wang13,14,15, Jyh-Horng Sheu16,17,18,19.
Abstract
Three new steroids, petasitosterones A and B (1 and 2) and a spirosteroid petasitosterone C (3), along with eight known steroids (4-11), were isolated from a Formosan marine soft coral Umbellulifera petasites. The structures of these compounds were elucidated by extensive spectroscopic analysis and comparison of spectroscopic data with those reported. Compound 3 is a marine steroid with a rarely found A/B spiro[4,5]decane ring system. Compounds 1-3 and 5 displayed inhibitory activity against the proliferation of a limited panel of cancer cell lines, whereas 2 and 5 exhibited significant anti-inflammatory activity to inhibit nitric oxide (NO) production. The inhibitory activities for superoxide anion generation and elastase release of compounds 1-11 were also examined to evaluate the anti-inflammatory potential, and 2-4 were shown to exhibit significant activities.Entities:
Keywords: Umbellulifera petasites; anti-inflammatory activity; cytotoxic activity; soft coral; steroid
Mesh:
Substances:
Year: 2016 PMID: 27727166 PMCID: PMC5082328 DOI: 10.3390/md14100180
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–11.
1H and 13C NMR spectroscopic data of 1–3.
| 1 | 2 | 3 | ||||
|---|---|---|---|---|---|---|
| Position | δC (mult.) a | δH ( | δC (mult.) a | δH ( | δC (mult.) a | δH ( |
| 1 | 155.4, CH c | 6.97 d (10.4) | 155.0, CH | 6.88 d (10.0) | 153.3, CH | 6.82 d (10.0) |
| 2 | 127.7, CH | 6.21 dd (10.4, 2.0) | 127.8, CH | 6.19 dd (10.0, 2.0) | 127.1, CH | 6.18 dd (10.0, 1.6) |
| 3 | 186.4, C | 186.3, C | 186.0, C | |||
| 4 | 123.9, CH | 6.06 s | 124.0, CH | 6.06 s | 129.1, CH | 6.14 s |
| 5 | 169.0, C | 168.5, C | 161.8, C | |||
| 6 | 32.8, CH2 | 2.45 td (13.6, 4.0) | 32.7, CH2 | 2.45 td (13.6, 4.0) | 34.9, CH2 | 1.99 m |
| 2.38 m | 2.38 m | 1.77 m | ||||
| 7 | 33.3, CH2 | 1.95 m | 33.2, CH2 | 1.97 m | 30.1, CH2 | 2.01 m |
| 1.10 m | 1.07 m | 1.40 m | ||||
| 8 | 35.6, CH | 1.63 m | 35.4, CH | 1.64 m | 42.0, CH | 1.81 m |
| 9 | 46.4, CH | 1.47 m | 46.6, CH | 1.23 m | 49.8, CH | 1.80 m |
| 10 | 43.0, C | 42.9, C | 51.8, C | |||
| 11 | 30.6, CH2 | 1.75 m | 26.8, CH2 | 2.01 m | 26.7, CH2 | 1.45 m |
| 1.87 m | 1.77 m | 1.35 m | ||||
| 12 | 70.9, CH | 3.79 br s | 74.2, CH | 4.75 br s | 74.0, CH | 4.69 br s |
| 13 | 45.9, C | 45.1, C | 46.3, C | |||
| 14 | 47.0, CH | 1.91 m | 48.1, CH | 1.54 m | 49.5, CH | 1.70 m |
| 15 | 23.6, CH2 | 1.67 m | 23.2, CH2 | 1.68 m | 23.6, CH2 | 1.72 m |
| 1.17 m | 1.19 m | 1.29 m | ||||
| 16 | 26.7, CH2 | 1.91 m | 26.2, CH2 | 1.90 m | 26.4, CH2 | 1.94 m |
| 1.32 m | 1.36 m | 1.42 m | ||||
| 17 | 46.7, CH | 1.53 m | 47.5, CH | 1.81 m | 47.3, CH | 1.79 m |
| 18 | 12.7, CH3 | 0.72 s | 12.8, CH3 | 0.79 s | 12.8, CH3 | 0.72 s |
| 19 | 18.5, CH3 | 1.20 s | 18.4, CH3 | 1.18 s | 19.2, CH3 | 1.90 d (1.2) |
| 20 | 39.8, CH | 2.21 m | 38.6, CH | 2.24 m | 38.6, CH | 2.24 m |
| 21 | 20.0, CH3 | 1.00 d (6.8) | 19.7, CH3 | 0.98 d (6.4) | 19.9, CH3 | 0.99 d (6.4) |
| 22 | 155.0, CH | 6.98 dd (15.6, 10.0) | 153.3, CH | 6.61 dd (15.6, 10.0) | 153.2, CH | 6.61 dd (15.6, 9.6) |
| 23 | 119.0, CH | 5.83 d (15.6) | 119.6, CH | 5.77 d (15.6) | 119.7, CH | 5.76 d (15.6) |
| 24 | 167.4, C | 166.6, C | 166.6, C | |||
| OMe | 51.6, CH3 | 3.74 s | 51.4, CH3 | 3.73 s | 51.5, CH3 | 3.71 s |
| OAc | 169.3, C | |||||
| 21.0, CH3 | 2.04 s | |||||
a Spectrum recorded at 100 MHz in CDCl3; b Spectrum recorded at 400 MHz in CDCl3; c Attached protons were deduced by DEPT experiment.
Figure 2Selected COSY and HMBC correlations of 1–3.
Figure 3Selected NOE correlations for 1 and 2.
Figure 4Selected NOE correlations for 3.
Cytotoxicity (IC50 μg/mL) of compounds 1–3 and 5.
| Compound | Cell Lines IC50 (μg/mL) | ||
|---|---|---|---|
| K-562 | MOLT-4 | DLD-1 | |
| ─ b | ─ | 6.4 ± 1.4 | |
| ─ | 12.1 ± 4.5 | 5.8 ± 1.7 | |
| ─ | ─ | 15.2 ± 3.5 | |
| 13.5 ± 3.1 | 5.9 ± 1.9 | 9.7 ± 3.2 | |
| Doxorubicin a | 0.45 ± 0.08 | 0.005 ± 0.02 | 0.2 ± 0.1 |
a Clinical anticancer drug used as a positive control; b ─: IC50 > 40 μg/mL. Results are presented as mean ± S.E.M. (n = 3–5).
Effect of 1–11 on superoxide anion generation and elastase release in fMLP/CB induced human neutrophils.
| Compound | Superoxide Anion | Elastase Release |
|---|---|---|
| IC50 (μM) a | IC50 (μM) a | |
| >10 *** | >10 | |
| 4.43 ± 0.23 *** | >10 *** | |
| 2.76 ± 0.92 *** | >10 * | |
| >10 | 6.80 ± 0.18 *** | |
| >10 | >10 *** | |
| >10 | >10 | |
| >10 | >10 | |
| >10 | >10 | |
| >10 | >10 | |
| >10 | >10 | |
| >10 | >10 *** |
a Concentration necessary for 50% inhibition (IC50). Results are presented as mean ± S.E.M. (n = 3–5). * p < 0.05, *** p < 0.001 compared with the control.
Figure 5Nitric oxide (NO) production and cell viabilities of compounds 1–11 in LPS-stimulated RAW264.7 cells (a) at 10 μg/mL (b) at 5 μg/mL. a AG: aminoguanidine used as a positive control.